Quantum BioPharma wins FDA clearance for Lucid-MS pivotal Phase 2 trial in progressive multiple sclerosis - QNTM News | RalliesQuantum BioPharma wins FDA clearance for Lucid-MS pivotal Phase 2 trial in progressive multiple sclerosis
Q
QNTM• FDA clears pivotal Lucid-MS Phase 2 trial
- Quantum BioPharma received FDA clearance on Aug. 10, 2026 to start a pivotal Phase 2 Lucid-MS trial in progressive multiple sclerosis.
- Results have not been presented; the randomized, double-blind, placebo-controlled study will generate future clinical data.
- The trial advances a patented neuroprotective program into the next development stage, targeting a high unmet-need segment in multiple sclerosis.
- Liquidity as of Q2 2026 stood at about US$9.5 million, supporting planned operations through at least October 2027.
